Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Latest preclinical studies reveal significant improvements in stability, efficacy, and KRAS targeting range for next-generation siRNA candidate SIL-204 Silexion Therapeutics Corp. (NASDAQ: SLXN...
New analysis from Silexion's Phase 2 trial of LODER shows a 56% objective response rate (ORR) and 67% resectability improvement in non-resectable pancreatic cancer Silexion Therapeutics Corp...
Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the...
RUNNEMEDE, N.J., Aug. 15 /PRNewswire-FirstCall/ -- Sielox, Inc. (OTC:SLXN) (BULLETIN BOARD: SLXN) , a developer, designer and distributor of security solution and industrial vision products...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0598 | -19.6710526316 | 0.304 | 0.3097 | 0.2312 | 740031 | 0.27055464 | CS |
| 4 | -0.2038 | -45.4910714286 | 0.448 | 0.46 | 0.2312 | 1662923 | 0.37678631 | CS |
| 12 | -4.3258 | -94.6564551422 | 4.57 | 4.65 | 0.2312 | 3258717 | 0.7936329 | CS |
| 26 | -4.3258 | -94.6564551422 | 4.57 | 4.65 | 0.2312 | 3258717 | 0.7936329 | CS |
| 52 | -4.3258 | -94.6564551422 | 4.57 | 4.65 | 0.2312 | 3258717 | 0.7936329 | CS |
| 156 | -4.3258 | -94.6564551422 | 4.57 | 4.65 | 0.2312 | 3258717 | 0.7936329 | CS |
| 260 | -4.3258 | -94.6564551422 | 4.57 | 4.65 | 0.2312 | 3258717 | 0.7936329 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
